Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: A center for international blood and marrow transplant research study

Anita D'Souza, Angela Dispenzieri, Baldeep Wirk, Mei Jie Zhang, Jiaxing Huang, Morie A. Gertz, Robert A. Kyle, Shaji Kumar, Raymond L. Comenzo, Robert Peter Gale, Hillard M. Lazarus, Bipin N. Savani, Robert F. Cornell, Brendan M. Weiss, Dan T. Vogl, César O. Freytes, Emma C. Scott, Heather J. Landau, Jan S. Moreb, Luciano J. CostaMuthalagu Ramanathan, Natalie S. Callander, Rammurti T. Kamble, Richard F. Olsson, Siddhartha Ganguly, Taiga Nishihori, Tamila L. Kindwall-Keller, William A. Wood, Tomer M. Mark, Parameswaran Hari

Research output: Contribution to journalArticlepeer-review

167 Scopus citations


Purpose: Autologous hematopoietic cell transplantation, or autotransplantation, is effective in light-chain amyloidosis (AL), but it is associated with a high risk of early mortality (EM). In a multicenter randomized comparison against oral chemotherapy, autotransplantation was associated with 24% EM. We analyzed trends in outcomes after autologous hematopoietic cell transplantation for AL in North America. Patients and Methods: Between 1995 and 2012, 1,536 patients with AL who underwent autotransplantation at 134 centers were identified in the Center for International Blood and Marrow Transplant Research database. EM and overall survival (OS) were analyzed in three time cohorts: 1995 to 2000 (n = 140), 2001 to 2006 (n = 596), and 2007 to 2012 (n = 800). Hematologic and renal responses and factors associated with EM, relapse and/or progression, progression-free survival and OS were analyzed in more recent subgroups from 2001 to 2006 (n = 197) and from 2007 to 2012 (n = 157) Results: Mortality at 30 and 100 days progressively declined over successive time periods from 11% and 20%, respectively, in 1995 to 2000 to 5% and 11%, respectively, in 2001 to 2006, and to 3% and 5%, respectively, in 2007 to 2012. Correspondingly, 5-year OS improved from 55% in 1995 to 2000 to 61% in 2001 to 2006 and to 77% in 2007 to 2012. Hematologic response to transplantation improved in the latest cohort. Renal response rate was 32%. Centers performing more than four AL transplantations per year had superior survival outcomes. In the multivariable analysis, cardiac AL was associated with high EM and inferior progression-free survival and OS. Autotransplantation in 2007 to 2012 and use of higher dosages of melphalan were associated with a lowered relapse risk. A Karnofsky score less than 80 and creatinine levels 2 mg/m2 or greater were associated with worsened OS. Conclusion: Post-transplantation survival in AL has improved, with a dramatic reduction in early posttransplantation mortality and excellent 5-year survival.

Original languageEnglish (US)
Pages (from-to)3741-3749
Number of pages9
JournalJournal of Clinical Oncology
Issue number32
StatePublished - Nov 10 2015

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: A center for international blood and marrow transplant research study'. Together they form a unique fingerprint.

Cite this